Reasons to hope and reasons to keep perspective on a vaccine

vaccinations

(CDC, Unsplash)

This article is brought to you thanks to the collaboration of The European Sting with the World Economic Forum.

Author: Stéphane Bancel, Chief Executive Officer, Moderna


  • There are 123 SARS-CoV-2 vaccines under development and seven that have entered human trials.
  • Any potential vaccines need to be manufactured to scale in this pandemic setting.
  • We must assess the potential speed with which a vaccine candidate can move towards approval.

In the face of an immense burden of disease and an unfathomable death toll from COVID-19, the world today has an intense need for hope. A degree of hope does come in some regions from diminishing numbers of cases, hospitalizations and deaths, caused by extreme restrictions on commerce, travel and social interaction.

Additional hope, sometimes ill-informed, comes from the development of potential therapeutics and vaccines. According to the Milken Institute, there are some 200 therapeutics being developed as possible treatments for COVID-19; and a remarkable 123 vaccines under development to prevent against infection by SARS-CoV-2, the virus responsible for causing COVID-19.

 

The company I lead, Moderna, Inc., is a clinical stage biotechnology company whose vaccine candidate against SARS-CoV-2, called mRNA-1273, was the first to enter human clinical trials in the United States, back on March 16. To date, this vaccine continues to progress positively through clinical trials. As such, a great deal of hope and public attention has been focused on our company and on this innovative potential medicine.

What I would like to do is to encourage you not to abandon hope in the context of the COVID-19 pandemic but ask that you tie your hope firmly to advancements in medical science. This will prevent you from reacting to well-meaning but potentially misguided enthusiasm or doubts. I will also suggest where specifically to look for validated elements of hope. My comments will focus on vaccines, since that is where my experience resides with respect to COVID-19.

My initial piece of guidance is this: be cautious of the sheer count of vaccine candidates. One hundred and twenty-three is a big number, but starting to develop a vaccine candidate is far different from bringing one to use in large populations. Our perspective at Moderna is that the only competitor we are racing against is the SARS-CoV-2 virus and the resulting devastation it brings. To us, more vaccines are welcome in this battle – and they are critical to addressing the level of human need around the world.

Don’t take false hope from the number of vaccine candidates; vaccines must move from development into clinical trials with humans, as an early step in progress towards eventual use. As of today, thankfully, there are at least seven vaccine candidates against the SARS-CoV-2 virus that have already entered human trials.

Beside ours, the six others come from the Beijing Institute of Biological Products, BioNTech (BNT162), CanSino Biologics (Ad5-nCoV), Inovio Pharmaceuticals (INO-4800), Sinovac Biotech, and University of Oxford (ChAdOx1 nCoV-19). This progress in a record timeframe is indeed encouraging – and a legitimate, medical reason for hope – but, as a number, seven is a long way from 123.

Public and private development landscape of SARS-CoV-2 vaccine.
More than 70% of the groups leading vaccine research are from private firms.

Now, within the set of potential vaccines that do make it into human trials, here are additional elements that I encourage you to watch for in order to engender true hope:

First, watch for specific early clinical indicators of safety and effectiveness. Vaccine candidates will typically be tested early on in animals, both to look for biological reactions that are consistent with appropriate immune system responses, as well as to see if the vaccine can prevent disease. Immune responses are assessed in the lab. Testing whether the vaccine can prevent disease will generally be done by challenging animals with the virus itself, and observing whether vaccinated animals actually avoid getting the disease.

Then, in humans, early trials will be conducted in relatively small numbers of healthy individuals. Those participants will be followed closely – first to assess safety and second to assess the production of neutralizing antibodies. Safety is relatively straightforward, since one is looking for the absence of serious adverse events. The presence of neutralizing antibodies indicates that the vaccine is creating substances that would be expected to defend a cell from the invading virus. In this case, it would be an indication that the vaccine may have rendered SARS-CoV-2 no longer infectious.

Next, to generate real hope, you must assess any potential vaccines in the context of whether they can be manufactured to scale in this pandemic setting. In the face of COVID-19, sponsors of vaccine candidates who cannot create product at the scale of tens or hundreds of millions of doses per month are probably not relevant in bolstering our hope at a global level. For our company, which has been previously in an R&D mode, recognizing this fact meant needing to execute a strategic production/supply agreement with a global partner that could rapidly amplify our volume to as much as a billion doses of vaccine per year.

Finally, the last element to secure hope is that you must assess the potential speed with which a vaccine candidate can move towards approval. In this case, I would be less concerned that a company has commercial rights to sell its vaccine, but more that relatively broad access to the vaccine may be granted to high-risk or other populations through widespread clinical trials, or through regulatory action by various governments. In the case with Moderna, we know that these regulatory paths are complex and, unless addressed early and with focus and scientific rigour, can create inadvertent delays in getting critical vaccines to vulnerable populations around the world.

What is the World Economic Forum doing about the coronavirus outbreak?

A new strain of Coronavirus, COVID 19, is spreading around the world, causing deaths and major disruption to the global economy.

Responding to this crisis requires global cooperation among governments, international organizations and the business community, which is at the centre of the World Economic Forum’s mission as the International Organization for Public-Private Cooperation.

The Forum has created the COVID Action Platform, a global platform to convene the business community for collective action, protect people’s livelihoods and facilitate business continuity, and mobilize support for the COVID-19 response. The platform is created with the support of the World Health Organization and is open to all businesses and industry groups, as well as other stakeholders, aiming to integrate and inform joint action.

As an organization, the Forum has a track record of supporting efforts to contain epidemics. In 2017, at our Annual Meeting, the Coalition for Epidemic Preparedness Innovations (CEPI) was launched – bringing together experts from government, business, health, academia and civil society to accelerate the development of vaccines. CEPI is currently supporting the race to develop a vaccine against this strand of the coronavirus.

My hope is that this message does not bring you undue concern about the potential for vaccines to prevent COVID-19, but instead gives you the tools to build legitimate confidence in where we and other companies are in combatting this pandemic. I can assure readers that I and my colleagues at Moderna share a humble confidence as we battle this enemy, and we approach every day with enthusiasm and unlimited energy in contributing in every way we can.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Catalysing change for gender equality, co-authored by two United Nations Under-Secretary Generals

Vaccination: understanding the challenges surrounding COVID-19 vaccination campaigns

How cities are failing to be inclusive – and what they can do about it

AI can wreak havoc if left unchecked by humans

The challenge to be a good healthcare professional

Total US cases quadruple in one week – Today’s coronavirus updates

How wealthy people transmit this advantage to their children and grand children

Amazon sinks while our breath sinks

Sudan Partnership Conference: EU mobilises more support for Sudan’s transition

Feeding families remains complex task in war-torn Syria – UN relief agency

Worldwide consumer confidence has shot up to its highest level for four years according to a survey of 130 Global Retail leaders

4 steps to using AI in an environmentally responsible way

Three experts on why eradicating plastic pollution will help achieve gender equality

What happens when you toss your water bottle in the trash?

Traditional finance is failing millennials. Here’s how investing needs to change

Falling inflation urges ECB to introduce growth measures today

Turkish and Greek Cypriot leaders ready for talks with UN chief on improved relations

Young people are not a nameless, faceless mass. So why do we treat them as such?

World Retail Congress Dubai 2016: Retail’s night of nights

More answers from Facebook ahead of Parliament hearing today

Competition: Commission invites stakeholders to provide comments on the application of EU competition law to collective bargaining agreements for self-employed

Hunger in Yemen: WFP considers aid suspension in face of repeated interference by some Houthi leaders

The silent code blue- a call for health worker’s safety

How do we upskill a billion people by 2025? Leadership and collaboration will be key

Portugal: €4.66 million in aid for 1,460 dismissed workers and jobless young

OECD household income up 0.7% in first quarter of 2018, outpacing GDP growth

Flying cars and driverless buses – the future of urban mobility has landed

Restoring prospect of peace in Middle East is ‘our shared responsibility’ UN envoy tells Security Council

‘Make healthy choices’ urges UN agency, to prevent and manage chronic diabetes

Why diversity needs your star power, as well as sponsors

Nordic companies prove doing good is good for the bottom line

Final turnout data for 2019 European elections announced

Why your next car is a bike

Islamophobia is driving more US Muslims to become politically engaged, suggests report

State aid: Commission approves €400 million of public support for very high-speed networks in Spain

Rule of law conditionality: MEPs strike a deal with Council

Governments should step up their efforts to give people skills to seize opportunities in a digital world

Gaza blockade causes ‘near ten-fold increase’ in food dependency, says UN agency

Abuse of authority provisions adopted by the Senate raise concerns over Brazil’s capacity to ensure independence of prosecutors and judges in fighting corruption

EU Elections: new rules to prevent breaches of data used to influence elections

Tackling Youth Unemployment

The EU can afford to invest trillions in support of employment

EU-U.S. Privacy Shield: Third review welcomes progress while identifying steps for improvement

10 technology trends to watch in the COVID-19 pandemic

Eurozone business activity again on upwards path

European Citizens’ Initiative: Commission decides to register 2 new initiatives

Afghanistan: UN condemns blasts that leave 8 dead at cricket stadium

The racial wealth gap in the US is affecting its citizens and its economy – this is how

On sidelines of UN climate summit, US President calls for protection of religious freedom

Better air pollution data is helping us all breathe easier. Here’s how

Criminals thrive on data abundance – here’s how we’ll catch them

Humanitarian visas would reduce refugees’ death toll

A European young student shares his thoughts on Quality Education

Future EU-UK Partnership: European Commission takes first step to launch negotiations with the United Kingdom

Our indispensable problem: the paradox of modern plastics

Consumers and businesses to save money thanks to new EU cross-border payments rules

Education critical to ensure future of forests, and reverse their destruction

This wristband tells you what food to buy based on your DNA

InvestEU Fund: boost for sustainable, innovative and social investment

Quality of Europe’s bathing waters remains high, latest annual assessment finds

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s